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Abstract. Vitiligo is a chronic disease characterized 
by the dysfunction or destruction of melanocytes with 
secondary depigmentation. The aim of the present study 
was to determine the prevalence of vitiligo associated with 
autoimmune rheumatic diseases. The clinical records from 
a 10-year database of patients with rheumatic diseases 
and associated vitiligo was analysed, with one group of 
patients having autoimmune rheumatic disease and another 
non-autoimmune rheumatic disease. Available serum samples 
were used to assess the anti-melanocyte antibodies. A total 
of 5,251 individual clinical files were archived in the last 
10 years, and these patients underwent multiple rheumatology 
consultations, with 0.3% of the group presenting with vitiligo. 
The prevalence of vitiligo in the autoimmune rheumatic 
disease group was 0.672%, which was mainly associated with 
lupus and arthritis. However, patients with more than one 
autoimmune disease had an increased relative risk to develop 
vitiligo, and anti-melanocyte antibodies were positive in 92% 
of these patients. By contrast, the prevalence was 0.082% in 
the group that lacked autoimmune rheumatic disease and 
had negative autoantibodies. In conclusion, the association 
between vitiligo and autoimmune rheumatic diseases was 
relatively low. However, the relative risk increased when there 
were other autoimmune comorbidities, such as thyroiditis or 
celiac disease. Therefore, the presence of multiple autoimmune 
syndromes should be suspected.
Introduction
Vitiligo is a skin disease characterized by dysfunction or 
destruction of melanocytes with secondary depigmentation, 
which constitutes the pathophysiological hallmark of the 
disease. The pathogenesis of vitiligo involves multiple factors. 
In 1950, Lerner proposed the neural theory (1). Since then, 
different evolving theories for the pathogenesis of vitiligo have 
been mentioned, including susceptibility genes, autoimmune 
response, abnormalities in the melanocytes and/or cellular 
damage from oxidative stress.
Genes for generalized vitiligo (GV) include XBP1, FOXP3, 
NALPq, TYR, and TLSP (2). Additionally, certain MHC genes 
are also associated with vitiligo, including the HLA-DRB1*07, 
HLA-A2 and HLA-B17 alleles. Similarly, SNAPs genotyping 
studies have demonstrated that the 6q27 chromosome is linked 
to this skin depigmentation disorder (3). The pathophysiology 
of autoimmune vitiligo involves humoral and cellular immunity 
by mechanisms that produce melanocyte damage. Clinically, 
depigmentation can be a unique symptom associated with auto-
antibody production and/or cell hypersensitivity. However, in a 
few cases of GV, the skin disease can be associated with other 
autoimmune diseases. With respect to the mechanisms involved 
in the autoimmune destruction of melanocytes, CD8 T cells 
appear to trigger melanocyte damage. Then, vitiligo antigens 
are released by cytolysis. Therefore, the initial insult is followed 
by a humoral autoimmune response against vitiligo-associated 
autoantigens, including MART-1, tyrosinase, and gp100 (2-11).
The epidemiology of this disease indicates that the 
prevalence of vitiligo ranges from 0.5 to 1% of the general 
population, and the disease is equally distributed in females 
and males (12). Considering that vitiligo is a common disease 
associated with various autoimmune diseases and that these 
comorbidities are usually evaluated as separate clinical enti-
ties, it is of interest to define the rheumatic comorbidities that 
can be associated with vitiligo as part of a multi-autoimmune 
syndrome, wherein this designation applies to the association 
of three or more autoimmune diseases in the same patient.
The aim of the present study was to determine the associa-
tion of vitiligo with multiple autoimmune rheumatic diseases 
in a database covering a period of 10 years.
Materials and methods
Subjects. The clinical files of patients who were treated in the 
Department of Rheumatology from 2005 and 2015 were reviewed. 
Using the data files, the main disease that led to the evaluation 
was identified. Subsequently, the number of patients with or 
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without rheumatic autoimmune diseases such as osteoarthritis, 
lumbalgia or tendinitis associated with vitiligo was determined. 
Each patient was reviewed by a skilled rheumatologist and 
dermatologist, respectively, and clinical criteria for disease 
for classification in each autoimmune disease was followed. 
Additionally, in each patient with vitiligo, the availability of 
serum samples stored in a freezer was determined, allowing for 
evaluation of the anti-melanocyte and anti-tyrosinase antibodies, 
which are markers of autoimmune vitiligo. Additionally, a group 
of rheumatic patients lacking autoimmune disease was included 
as the control group. Autoimmune co-morbidities and autoanti-
bodies were assessed in the two groups.
The study was approved by the ethics committee of 
Universidad Autónoma de Zacatecas (Zacatecas, Mexico). 
Patient consent was obtained from each patient.
Anti-melanocyte antibodies. An intradermal nevus, ~0.5 cm in 
diameter, of the preauricular region in a patient who was 27 years 
with no clinical or serological manifestations of autoimmunity 
was removed for cosmetic reasons. Prior to this procedure, a 
signed authorization was obtained to use part of the nevus as 
an antigenic source. The lesion was divided into two parts; one 
part was sent for histopathological analysis and another part was 
used for indirect immunofluorescence studies (13). The tissue 
was transported to the laboratory on ice, and was subsequently 
embedded in Tissue-Tek OCT® (Leica Biosystems, Nussloch, 
Germany) and frozen at -20˚C. Tissue samples were cut at 4 µm 
using a cryostat (-20˚C), and the slices were fixed on slides. The 
serum samples were tested at dilutions of 1:20 to 1:160, incubated 
with the antigenic source for 30 min in a moist chamber, and 
the slides were washed three times in phosphate-buffered saline 
(PBS) (pH 7.2). This step was followed by a 30-min incubation 
with polyvalent FITC-labelled rabbit anti-human antiserum 
(cat. no.  F4637; 1:80; Sigma-Aldrich, St. Louis, MO, USA). 
After three additional PBS washes, the slides were mounted 
with glycerol-PBS (9:1), and two independent observers evalu-
ated the samples using an Olympus B-Max BX-40 fluorescence 
microscope (Olympus, Tokyo, Japan) in a blinded manner.
Anti-tyrosinase antibodies. The specificity of the sera to 
tyrosinase was evaluated in triplicate by ELISA as previously 
described (14) with modifications. Polystyrene plates were 
covered overnight with 10 µg of tyrosinase fragment 369-377 
(cat. no. T8455; Sigma-Aldrich) dissolved in 70% ethanol. 
Uncovered sites were neutralized with 4% BSA. The serum 
samples were diluted 1:100 and applied into the microwells. 
They were then incubated for 2 h at room temperature. After 
3 washes, the samples were incubated with secondary anti-
body goat anti-human IgG HRP (cat. no. sc-2453; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) for 1 h. After washing 
again, the colour reaction was developed with TMB in a 30-min 
incubation. The reaction was then stopped with 0.5 M sulfuric 
acid and the microplates were read at 450 nm using a microplate 
reader (Thermo Fisher Scientific, Inc., Shanghai, China).
Other autoantibodies. Anti-thyroid antibodies on a commer-
cial antigenic source, anti-nuclear antibodies in HEp-2 
cells (Immuno Concepts, Inc., Sacramento, CA, USA) and 
anti-epithelial antibodies, using as antigen source cow nose, 
were evaluated with indirect immunofluorescence.
Statistical analysis. The probability of the association between 
vitiligo and certain autoimmune rheumatic disease was calcu-
lated using the χ2 test. The relative risk and odds ratios (OR), 
with 95% of confidence intervals, were determined using the 
Prism software program (GraphPad Software, Inc., San Diego, 
CA, USA). P<0.0001 was considered statistically significant.
Results
Clinical records. In 10 years, a total of 5,251 records were filed. 
Each record corresponded to one patient, and these patients 
were evaluated over multiple rheumatology consultations. 
From these, 2,824 files corresponded to patients with autoim-
mune disease (54%), while the remaining 2,427 (46%) had 
other rheumatic diseases, including degenerative, metabolic or 
other diseases. The most prevalent autoimmune disease was 
exhibited by rheumatoid arthritis (RA) patients who met the 
ACR/EULAR classification criteria (15), which accounted for 
43% of autoimmune rheumatic diseases. This was followed by 
26% with lupus erythematosus, which met the ACR revised 
criteria for SLE (16). Other diseases, such as scleroderma, 
accounted for a lower proportion of the cases (2.4%). Of the 
total number of autoimmune rheumatic diseases, 19 patients, 
16 women and 3 men, with a mean age of 36 years, had 
GV (17), corresponding to 0.672% of the sample. Clinically, 
most of the patients had skin depigmentation distributed along 
the face, hands and trunk (Fig. 1). In contrast to the control 
group, only one patient with osteoarthritis had localized spots 
of vitiligo, and the prevalence was 0.0412%. The differences 
between the two groups were significant (P<0.0002) (Fig. 1). 
Of note, the relative risk for developing vitiligo was signifi-
cantly increased in patients who had an additional autoimmune 
comorbidity, such as celiac of 33% (18) or thyroid disease in 
19% (19) (Table I).
Autoantibodies. Ninety-two percent of the group with autoim-
mune rheumatic disease and associated vitiligo tested positive 
for anti-melanocyte antibodies. Therefore, fluorescence was 
observed in scattered melanocytes along the epidermis as well 
as in melanosomes and melanin granules for some patients. 
The antibody titres varied across the patients. By contrast, 
the anti-tyrosinase antibodies were positive in 84% of the 
patients (Fig. 2).
Other shared autoantibodies included rheumatoid factor 
and anti-CCP, ANA, anti-thyroid and anti-epithelial antibodies 
although none of the patients had symptoms of pemphigus.
Discussion
Vitiligo is a disease characterized by the loss of pigment-
producing cells. The disease has psychological and social 
consequences, and in some cases it is caused by autoimmunity. 
The aim of the present study was to determine the prevalence 
of vitiligo associated with other autoimmune rheumatic 
diseases. The main results of the present study were as follows. 
First, the prevalence of vitiligo associated with autoimmune 
rheumatic disease was 0.672. Second, autoantibodies against 
vitiligo-associated antigens were present in the 92% of the 
autoimmune group. Third, RA and lupus were frequently 
associated with vitiligo, although the relative risk of vitiligo 
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as an event occurring, measured the magnitude of association 
using the cumulative incidence, rather than the total number. 
This measure showed the relative risk of vitiligo in RA was not 
different than the prevalence reported in the general popula-
tion. Notably, the vitiligo risk was markedly increased when 
the two diseases were associated with thyroid or celiac disease.
Vitil igo has been extensively studied. In 1979, 
Goudie et al (20) brought attention to the comorbidities 
of vitiligo, suggesting that this disease constituted a set 
of mosaic patches with distinctive shared characteristics 
of autoimmunity. Traditionally, vitiligo alone has been 
extensively studied worldwide, including in Latin America. 
The present study was performed in the mestizo popula-
tion of a central region of Mexico. The mestizo population 
results from a mixture between Amerindian Caucasian and 
African genes (21). In Mexico, the prevalence of vitiligo in 
children has been estimated as 2.6% (22). The present study 
addresses the prevalence of vitiligo in adult patients with 
rheumatic disease, and the global prevalence of vitiligo 
detected in the present study was 0.380, which is lower than 
Figure 1. The vitiligo prevalence in rheumatic diseases. (A) Total number of patients grouped into autoimmune and non-autoimmune rheumatic diseases. 
(B) Patients with autoimmune rheumatic diseases associated with vitiligo. (C) Hand from a patient with dermatomyositis, vitiligo and Crohn's disease (as 
shown in the intestinal histology). (D) Drawing shows the clinical overlap of vitiligo and the comorbidities in the present study. RA, rheumatoid arthritis; 
SLE, systemic lupus erythematosus; PSS, progressive systemic sclerosis; AS, ankylosing spondylitis; DM, dermatomyositis.
Table I. Relative risk for developing vitiligo.
Disease No. of patients Vitiligo Prevalence P-value Relative risk OR
NARD 2,427   1   0.041
ARD 2,829 19   0.672 0.0002 0.0612 0.0608
RA 1,899   6   0.315 0.0257 0.1304 0.1300
SLE    742   3   0.404 0.0148 0.1019 0.1015
Sjögren      91   1   1.098 0.0004 0.0374 0.0371
PSS      68   1   1.470 0.0001 0.0280 0.0276
DM      20   1   5.000 0.0001 0.0082 0.0078
Tyroiditis + RA or SLE      21   4 19.047 0.0001 0.0021 0.0017a
Celiac disease + SLE or RA        6   2 33.333 0.0001 0.0012 0.0008a
AS + Crohn's disease        4   1 25.000 0.0001 0.0016 0.0012a
OR, odds ratio; NARD, non-autoimmune rheumatic disease; ARD, autoimmune rheumatic disease; RA, rheumatoid arthritis; SLE, systemic 
lupus erythematosus; AS, ankylosing spondylitis. aHighly significant, P<0.0001.
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the 0.5-2% reported in the overall worldwide population 
by Krüger and Schallreuter (23). The differences with the 
present results can be explained by ethnic factors or different 
methodologies used in the patients included in each study. Of 
note, the prevalence of vitiligo is variable; for instance, the 
prevalence in the Korean population is 0.12% (24), while it is 
lower (0.093%) in a Chinese Shaanxi Province (25). In both 
instances, the prevalence in some Asiatic countries is lower 
than in the present study.
Concurrence of various autoimmune diseases in a single 
patient captured the attention of different clinical research 
groups, and diverse names have been given to these associated 
comorbidities, including polyautoimmunity, multiple auto-
immunity, and shared autoimmunity (26-30). The autoimmune 
rheumatic comorbidities associated with vitiligo are variable, 
including RA and psoriasis (31-33). In the Middle Eastern 
population, the association of vitiligo with RA is related to 
the TNFα-308 A/G promoter (34), which probably reflects that 
this cytokine participates in melanocyte destruction. Sjögren 
disease has been reported to be associated with vitiligo (35). 
Other autoimmune comorbidities that accompany rheumatic 
diseases and vitiligo include pernicious anemia (36), 
Graves' disease, autoimmune haemolytic anemia (37), thyroid 
and celiac disease and other pathologies (38-42). Common 
pathogenic mechanisms that are suggested to facilitate 
these comorbidities involve the protein tyrosine phosphatase 
non-receptor type 22 (PTPN22) gene, which seems to increase 
the susceptibility for one patient to have a cluster of different 
autoimmune diseases. This cluster includes type I diabetes, RA, 
autoimmune thrombocytopenia, inflammatory myopathies, 
Graves' disease, SLE, ANCA-associated vasculitis, and 
Cohn's disease (43). On the other hand, HLA-DQ pleiotropic 
genes are also involved in the pathogenesis of multiple 
autoimmunity (44).
In conclusion, based on the results of this study, the associa-
tion between vitiligo and one autoimmune rheumatic disease 
is relatively low, which is probably similar to the prevalence 
of vitiligo in the general population. Nevertheless, when this 
disease is associated with more than two autoimmune comor-
bidities, including thyroid or celiac disease, its relative risk 
is notably increased. In such a case, a multiple autoimmune 
syndrome should be suspected.
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